Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NY1R
|
|||
| Former ID |
DIB000392
|
|||
| Drug Name |
AC-3174
|
|||
| Synonyms |
GLP-1 agonist (type 2 diabetes), Amylin Pharmaceuticals; Glucagon-like peptide-1 receptor agonist (type 2diabetes/non-alcoholic steatohepatitis), Amylin Pharmaceuticals; (Leu14)exendin-4
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-alcoholic steatohepatitis [ICD-11: DB92.1; ICD-10: K75.8; ICD-9: 571.8] | Investigative | [1], [2], [3] | |
| Company |
Amylin Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C5H3BrClN
|
|||
| Canonical SMILES |
C1=CC(=NC=C1Cl)Br
|
|||
| InChI |
1S/C5H3BrClN/c6-5-2-1-4(7)3-8-5/h1-3H
|
|||
| InChIKey |
BZUUVQCSPHPUQA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 40473-01-6
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Agonist | [1], [2], [3] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Insulin secretion | ||||
| Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
| G alpha (s) signalling events | ||||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| Integration of energy metabolism | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006). | |||
| REF 2 | Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):463-77. | |||
| REF 3 | Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR). Rev Med Liege. 2014 Apr;69(4):214-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.